4.

The therapeutic gene, BikDD driven by Survivin-VISA and CMV promoter inhibited tumor growth and prolonged survival time than Ctrl group in the F4-Luc lung cancer orthotopic xenograft model. (A) SCID mice with intrathoracic injection of F4-Luc lung cancer cells were intravenously injected with 25 µg of liposomal plasmid DNA. Arrows indicate the therapy time points. The photon signals were quantified with Xenogen’s living imaging system to reflect the tumor size. Error bars indicate SEM. (B) Kaplan-Meier survival analysis was performed. The mean survival time was 36±2, 59±5, and 64±5 days in Ctrl, CMV-BikDD, and SV-BikDD groups, respectively. (C) BikDD driven by CMV or Survivin-VISA promoter was detected in the lung tissue from the mouse bearing lung cancers by RT-PCR two days later after the last treatment. ** indicated p value < 0.01.